A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
Latest Information Update: 30 Apr 2021
At a glance
- Drugs Evogliptin (Primary) ; Pioglitazone
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Dong-A ST
Most Recent Events
- 07 Jul 2019 Status changed from not yet recruiting to recruiting.
- 12 Apr 2019 New trial record